Astria Therapeutics Publishes Navenibart Phase 1a Healthy Subject Results In Annals of Allergy, Asthma & Immunology

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart's potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma & Immunology.

Overview of results from the Phase 1a trial of navenibart in healthy subjects:

• For all doses ≥300 mg, navenibart mean half-life ranged from 82 to 105 days, supporting the potential for administration every 3 and 6 months. Navenibart's inhibition of plasma kallikrein activity versus placebo was statistically significant (P<0.05).
• Navenibart was well-tolerated, with similar rates of adverse events between navenibart and placebo, and no serious adverse events were observed.
• Results demonstrated early proof of concept for navenibart as a potential long-acting therapy for HAE.